365 related articles for article (PubMed ID: 30391079)
1. Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer.
Canter DJ; Reid J; Latsis M; Variano M; Halat S; Rajamani S; Gurtner KE; Sangale Z; Brawer M; Stone S; Bardot S
Eur Urol; 2019 Mar; 75(3):515-522. PubMed ID: 30391079
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy.
Canter DJ; Freedland S; Rajamani S; Latsis M; Variano M; Halat S; Tward J; Cohen T; Stone S; Schlomm T; Bishoff J; Bardot S
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):102-107. PubMed ID: 31243337
[TBL] [Abstract][Full Text] [Related]
3. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
4. Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer.
Morris DS; Woods JS; Edwards B; Lenz L; Logan J; Flake DD; Mabey B; Bishoff JT; Cohen T; Stone S
Urol Oncol; 2021 Jun; 39(6):366.e19-366.e28. PubMed ID: 33257218
[TBL] [Abstract][Full Text] [Related]
5. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
[TBL] [Abstract][Full Text] [Related]
6. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
[TBL] [Abstract][Full Text] [Related]
7. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.
Cooperberg MR; Simko JP; Cowan JE; Reid JE; Djalilvand A; Bhatnagar S; Gutin A; Lanchbury JS; Swanson GP; Stone S; Carroll PR
J Clin Oncol; 2013 Apr; 31(11):1428-34. PubMed ID: 23460710
[TBL] [Abstract][Full Text] [Related]
8. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.
Cullen J; Rosner IL; Brand TC; Zhang N; Tsiatis AC; Moncur J; Ali A; Chen Y; Knezevic D; Maddala T; Lawrence HJ; Febbo PG; Srivastava S; Sesterhenn IA; McLeod DG
Eur Urol; 2015 Jul; 68(1):123-31. PubMed ID: 25465337
[TBL] [Abstract][Full Text] [Related]
9. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy.
Freedland SJ; Gerber L; Reid J; Welbourn W; Tikishvili E; Park J; Younus A; Gutin A; Sangale Z; Lanchbury JS; Salama JK; Stone S
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):848-53. PubMed ID: 23755923
[TBL] [Abstract][Full Text] [Related]
10. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
Nguyen PL; Haddad Z; Ross AE; Martin NE; Deheshi S; Lam LLC; Chelliserry J; Tosoian JJ; Lotan TL; Spratt DE; Stoyanova RS; Punnen S; Ong K; Buerki C; Aranes M; Kolisnik T; Margrave J; Yousefi K; Choeurng V; Davicioni E; Trock BJ; Kane CJ; Pollack A; Davis JW; Feng FY; Klein EA
Eur Urol; 2017 Nov; 72(5):845-852. PubMed ID: 28528811
[TBL] [Abstract][Full Text] [Related]
11. Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.
Tosoian JJ; Chappidi MR; Bishoff JT; Freedland SJ; Reid J; Brawer M; Stone S; Schlomm T; Ross AE
BJU Int; 2017 Dec; 120(6):808-814. PubMed ID: 28481440
[TBL] [Abstract][Full Text] [Related]
12. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort.
Cuzick J; Stone S; Fisher G; Yang ZH; North BV; Berney DM; Beltran L; Greenberg D; Møller H; Reid JE; Gutin A; Lanchbury JS; Brawer M; Scardino P
Br J Cancer; 2015 Jul; 113(3):382-9. PubMed ID: 26103570
[TBL] [Abstract][Full Text] [Related]
13. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of a cell-cycle progression score in men with prostate cancer managed with active surveillance after MRI-guided prostate biopsy--a pilot study.
Arsov C; Jankowiak F; Hiester A; Rabenalt R; Quentin M; Schimmöller L; Blondin D; Antoch G; Albers P
Anticancer Res; 2014 May; 34(5):2459-66. PubMed ID: 24778061
[TBL] [Abstract][Full Text] [Related]
15. Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.
Yamoah K; Johnson MH; Choeurng V; Faisal FA; Yousefi K; Haddad Z; Ross AE; Alshalafa M; Den R; Lal P; Feldman M; Dicker AP; Klein EA; Davicioni E; Rebbeck TR; Schaeffer EM
J Clin Oncol; 2015 Sep; 33(25):2789-96. PubMed ID: 26195723
[TBL] [Abstract][Full Text] [Related]
16. Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting.
Howard LE; Zhang J; Fishbane N; Hoedt AM; Klaassen Z; Spratt DE; Vidal AC; Lin D; Hitchins MP; You S; Freeman MR; Yamoah K; Davicioni E; Freedland SJ
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):419-428. PubMed ID: 31844180
[TBL] [Abstract][Full Text] [Related]
17. Multicenter Comparison of 17-Gene Genomic Prostate Score as a Predictor of Outcomes in African American and Caucasian American Men with Clinically Localized Prostate Cancer.
Cullen J; Lynch JA; Klein EA; Van Den Eeden SK; Carroll PR; Mohler JL; Knezevic D; Farrington TA; Lu R
J Urol; 2021 Apr; 205(4):1047-1054. PubMed ID: 33493001
[TBL] [Abstract][Full Text] [Related]
18. Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors.
Lalonde E; Alkallas R; Chua MLK; Fraser M; Haider S; Meng A; Zheng J; Yao CQ; Picard V; Orain M; Hovington H; Murgic J; Berlin A; Lacombe L; Bergeron A; Fradet Y; Têtu B; Lindberg J; Egevad L; Grönberg H; Ross-Adams H; Lamb AD; Halim S; Dunning MJ; Neal DE; Pintilie M; van der Kwast T; Bristow RG; Boutros PC
Eur Urol; 2017 Jul; 72(1):22-31. PubMed ID: 27815082
[TBL] [Abstract][Full Text] [Related]
19. The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation.
Tward J; Lenz L; Flake DD; Rajamani S; Yonover P; Olsson C; Kapoor DA; Mantz C; Liauw SL; Antic T; Fabrizio M; Salzstein D; Shore N; Albertson D; Henderson J; Lee SP; Gay HA; Michalski J; Hung A; Raben D; Garraway I; Lewis MS; Nguyen PL; Marshall DT; Brawer MK; Stone S; Cohen T
Int J Radiat Oncol Biol Phys; 2022 May; 113(1):66-76. PubMed ID: 34610388
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.
Cuzick J; Swanson GP; Fisher G; Brothman AR; Berney DM; Reid JE; Mesher D; Speights VO; Stankiewicz E; Foster CS; Møller H; Scardino P; Warren JD; Park J; Younus A; Flake DD; Wagner S; Gutin A; Lanchbury JS; Stone S;
Lancet Oncol; 2011 Mar; 12(3):245-55. PubMed ID: 21310658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
